This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Study to assess pharmacokinetic, pharmacodynamic, ...
Clinical trial

Study to assess pharmacokinetic, pharmacodynamic, safety and immunogenicity of a new adalimumab formulation in subjects with active rheumatoid arthritis.

Read time: 1 mins
Last updated:15th Jun 2012
To compare the new adalimumab formulation to the currently approved (current) adalimumab formulation in a dosing regimen of 40 mg eow for 24 weeks
Category Value
Study start date 2012-06-15

View full details